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SUMMARY
Genomic and protein-coding transcriptomic data have suggested that germ cell tumours (GCTs) of childhood are biologically dis-
tinct from those of adulthood. Global messenger RNA profiles segregate malignant GCTs primarily by histology, but then also by age,
with numerous transcripts showing age-related differential expression. Such differences are likely to account for the heterogeneous
clinico-pathological behaviour of paediatric and adult malignant GCTs. In contrast, as global microRNA signatures of human
tumours reflect their developmental lineage, we hypothesized that microRNA profiles would identify common biological abnormali-
ties in all malignant GCTs owing to their presumed shared origin from primordial germ cells. MicroRNAs are short, non-protein-cod-
ing RNAs that regulate gene expression via translational repression and/or mRNA degradation. We showed that all malignant GCTs
over-express the miR-371–373 and miR-302/367 clusters, regardless of patient age, histological subtype or anatomical tumour site.
Furthermore, bioinformatic approaches and subsequent Gene Ontology analysis revealed that these two over-expressed microRNAs
clusters co-ordinately down-regulated genes involved in biologically significant pathways in malignant GCTs. The translational
potential of this finding has been demonstrated with the detection of elevated serum levels of miR-371–373 and miR-302/367 mi-
croRNAs at the time of malignant GCT diagnosis, with levels falling after treatment. The tumour-suppressor let-7 microRNA family
has also been shown to be universally down-regulated in malignant GCTs, because of abundant expression of the regulatory gene
LIN28. Low let-7 levels resulted in up-regulation of oncogenes including MYCN, AURKB and LIN28 itself, the latter through a direct
feedback mechanism. Targeting LIN28, or restoring let-7 levels, both led to effective inhibition of this pathway. In summary, paediat-
ric malignant GCTs show biological differences from their adult counterparts at a genomic and protein-coding transcriptome level,
whereas they both display very similar microRNA expression profiles. These similarities and differences may be exploited for diag-
nostic and/or therapeutic purposes.
AIMS
The aim of this review was to focus on the biological studies of
malignant germ cell tumours (GCTs) and highlight similarities
and differences between tumours arising during childhood and
those arising in adulthood. In addition to considering genomic
and protein-coding transcriptomic changes, we will emphasize
findings from expression profiling studies of short non-protein-
coding RNAs, termed microRNAs, in GCTs. Our improving
knowledge of the molecular mechanisms underlying the patho-
genesis of GCTs is contributing to the identification of new
biomarkers and therapeutic targets, and the development of cli-
nico-biological algorithms for disease segmentation and risk
stratification. Combined with the developing collaborations
between international clinical trial groups, we can be cautiously
optimistic that these approaches will, in the foreseeable future,
improve the clinical management of the children, adolescents
and young adults affected by this disease (Murray et al., 2009;
Collinson et al., 2014; Stoneham et al., 2014).
BACKGROUND
Germ cell tumours are clinically and pathologically complex
neoplasms that occur from the neonatal period through to late
adulthood (Murray & Nicholson, 2010). They show extensive cli-
nico-pathological heterogeneity, for example in their incidence
rate, presentation and histology. Only 50% of GCTs present at
gonadal sites during childhood, whereas this figure increases to
95% in adulthood (Murray & Nicholson, 2010). GCTs display a
characteristic bimodal age distribution in childhood, with a
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relatively high incidence rate in the first few years of life, which
then declines to very low levels around 5 years of age, before
increasing again in adolescence. As a result, their incidence in
the paediatric (four per million) and older adult (14 per million)
populations remains markedly lower than in teenagers and
young adults (TYAs) (60 per million in males and eight per mil-
lion in females) (Murray et al., 2009).
Despite these clinical differences, all GCTs are believed to
originate from primordial germ cells (PGCs), regardless of
patient age, tumour site and histological subtype (Teilum, 1965).
Despite the common origin theory, the histological appearance
of GCTs varies depending on the type and degree of subsequent
differentiation. Those tumours that show extensive somatic dif-
ferentiation are referred to as teratomas and are generally con-
sidered benign, particularly in paediatric practice. Malignant
GCTs show varying degrees of differentiation and are classified
into seminoma (undifferentiated) and non-seminomatous
tumours [yolk sac tumour (YST), embryonal carcinoma (EC) and
choriocarcinoma (CHC)]. The latter tumours show yolk sac,
embryonal and trophoblastic/placental-like differentiation
respectively (Murray & Nicholson, 2010). In this review, the term
seminoma is used to collectively describe testicular seminomas,
ovarian dysgerminomas and extragonadal germinomas. Mixed
malignant GCTs also occur, which are composed of more than
one histological subtype. Clinical differences between GCTs aris-
ing in children and adults, along with experimental data, such as
the maturational stage and imprinting status of the originating
PGC, led Oosterhuis and Looijenga to propose a classification
system where GCTs are divided into five types (Oosterhuis &
Looijenga, 2005). Relevant to this review, ‘Type I’ tumours occur
in neonates and infants <5 years of age and predominantly com-
prise non-seminomatous teratomas and YSTs. ‘Type II’ tumours
include both non-seminomatous and seminomatous GCTs and
include testicular disease in patients >15 years and ovarian
tumours in those aged >4 years (Oosterhuis & Looijenga, 2005).
CLINICAL PERSPECTIVE
Malignant GCTs rapidly became a highly curable disease, even
when diagnosed at advanced clinical stages, with the advent of
cisplatin-based chemotherapy in the 1970s (Einhorn & Don-
ohue, 1977; Williams et al., 1987). However, up to 20% of
patients may still eventually die of their disease. Although paedi-
atric GCTs were initially treated with ‘adult’ type cisplatin-based
regimes, the long-term sequelae of such schedules were sub-
stantial, including pulmonary fibrosis (Osanto et al., 1992),
nephrotoxicity (Bosl et al., 1986), neuropathy (Glendenning
et al., 2010) and ototoxicity (Bokemeyer et al., 1996a; Strumberg
et al., 2002). Of particular concern are reports of increased risks
of early onset cardiovascular disease (Huddart et al., 2003) and
second malignancies (Travis et al., 1997, 2005) in survivors of
malignant GCT disease. These side effect profiles resulted in the
adoption of a carboplatin-based approach instead for affected
children in the UK, with comparable survival for all tumour
stages (Mann et al., 2000). However, carboplatin therapy has
been shown to be inferior to cisplatin in adults with malignant
testicular GCTs (TGCTs), although lower dose carboplatin
regimes have typically been used in this age-group owing to the
increased risk of myelosuppression (Bokemeyer et al., 1996b;
Horwich et al., 1997; Collinson et al., 2014). When attempting to
identify the optimal treatment schedules for such patients
however, the currently available clinical risk stratification sys-
tems are not sophisticated enough to truly distinguish those
GCT patients who will have excellent outcomes from those des-
tined to have poor outcomes. For example, within the Interna-
tional Germ Cell Consensus Classification (IGCCC) (1997) high-
risk group it is not possible to identify upfront at the time of
diagnosis the 55% of patients who will be chemotherapy resis-
tant (and have either refractory disease or show subsequent
relapse), from the 45% for whom four courses of standard cis-
platin-based chemotherapy (BEP) will be sufficient for cure.
Consequently, we need to extend our knowledge of GCT biology
and use it to develop combined clinico-biological risk stratifica-
tion algorithms, improved biomarkers and targets for the devel-
opment of novel therapeutic agents for patients with malignant
GCTs. This should ultimately lead to improved cure rates for
those patients who currently have poor outcomes in the IGCCC
(or equivalent risk stratification) intermediate- and high-risk dis-
ease groups and allow reduction of toxicity in those patient
groups truly defined as low-risk.
GENOMIC CHANGES
Atkin & Baker (1982) first described the detection of an iso-
chromosome of the short arm of chromosome 12 [i(12p)] in
TGCTs over three decades ago. This abnormality occurs in ~80%
of adult TGCTs, whereas more limited gain of 12p genomic
material is almost invariably present in the remaining cases
(Collinson et al., 2014). 12p gain is also a common cytogenetic
event in ovarian GCTs (Kraggerud et al., 2000). Gain of 12p
occurs regardless of histological subtype in adult gonadal malig-
nant GCTs. In contrast, 12p gain was initially thought to occur
rarely in paediatric malignant GCTs (Collinson et al., 2014), for
example described in only 1/16 (6%) of cases in a small cohort of
gonadal and extragonadal tumours that exclusively comprised
YST histology (Perlman et al., 2000). A larger study of 33 paediat-
ric gonadal and extragonadal malignant GCTs identified 12p
gain in just three cases (8%; one testicular and two ovarian
cases) (Schneider et al., 2001). Bussey et al. (2001) identified 12p
gain in 6/53 (11%) paediatric GCT cases and identified increased
prevalence in male (28%) compared with female (3%) patients.
More recently, a paediatric study which included a large propor-
tion of ovarian malignant GCTs and both seminoma and YST
histology, revealed 12p gain in 44% of cases, with an increasing
incidence with age: 53% in those aged 5–16 years compared with
29% in those <5 years (Palmer et al., 2007). These findings sug-
gest that genomic copy number imbalances can distinguish GCT
subgroups primarily by patient age, rather than by tumour site
or histology.
As the only consistent structural chromosomal abnormality in
malignant GCTs of adult patients, 12p gain is implicated in inva-
sive malignant GCT development. The observation that the pre-
invasive testicular lesion intratubular germ cell neoplasia
unclassified demonstrates a similar pattern of overall genomic
changes to those seen in invasive TGCTs, except for 12p gain,
supports this theory (Rosenberg et al., 2000; Summersgill et al.,
2001; Ottesen et al., 2003). Reports suggest that 12p gain in
TGCTs results in the activation of key stem cell genes which pro-
mote cellular proliferation (Korkola et al., 2006). However, the
identification of which specific genes on 12p are the fundamen-
tal universal ‘drivers’ of malignant GCT pathogenesis and which
are merely ‘passengers’ has been difficult to achieve. For
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example, adult testicular seminomas and ECs over-express stem
cell genes (e.g. NANOG) located at the common region of 12p
gain (12p13.31), suggesting that they are likely to be important
in tumorigenesis. However, other non-seminomatous tumours,
for example YSTs, which also have 12p gain, do not over-express
these genes, suggesting other mechanisms must be important.
Other genomic copy number imbalances in malignant GCTs
have also been described in adults. Commonly observed imbal-
ances include gains on chromosomes 1, 7, 8, 12, 21 and X, as well
as losses on 4, 5, 11, 13 and 18. However, none of these reported
abnormalities are as consistent as gain of 12p (Collinson et al.,
2014). A wide range of copy number imbalances has also been
described in paediatric malignant tumours, including gains on
chromosomes 1q, 2p, 3, 7, 8, 13, 14, 20q, 21 and X, as well as
losses on 1p36, 4q, 6q, 11, 13 and 18 (Collinson et al., 2014).
In the last few years, high-resolution approaches have become
available to interrogate genomic abnormalities and regions of
interest in far greater detail than has previously been possible. A
small study of 25 adult malignant testicular seminomas has been
published using this technique, which re-confirmed the pres-
ence of 12p gain (LeBron et al., 2011). Comparison of early- and
late-stage disease identified copy number variations that corre-
lated with progression, including 4q, 5p, 9q, 13q and 20p dele-
tions and 9q and 13q amplifications (LeBron et al., 2011).
Similar studies in childhood GCTs are ongoing and are likely to
reveal many novel aberrations which may account for the
observed differences in clinical behaviour and outcomes of these
tumours.
PROTEIN-CODING GENE EXPRESSION
Protein-coding transcriptomic studies have predominantly
been performed in adult TGCTs. A recent review article of 23
such studies highlighted common gene changes in TGCTs, eluci-
dating transcriptional changes associated with malignant trans-
formation and with differentiation patterns of malignant GCTs
(Alagaratnam et al., 2011). This study implicated both known
(KRAS, MYCN and TPD52) and novel (CCT6A, IGFBP3 and
SALL2) cancer genes in TGCT pathogenesis. Gene expression
patterns in malignant GCTs characteristic of embryonic stem
cells (ESCs) were confirmed and a distinctive transcriptomic
programme was identified for individual histological subtypes
(Alagaratnam et al., 2011). For seminoma, this included LZTS1;
for EC, DNMT3B, GAL and GPC4; for CHC CGA; and for YSTs
AFP, APOA2, BMP2, VTN and OTX2 (Alagaratnam et al., 2011).
Similarly, global mRNA gene expression profiles in paediatric
malignant GCTs completely segregated the two main histologi-
cal subtypes, YSTs and seminomas (Palmer et al., 2008). Within
individual histological subtypes, however, tumours shared simi-
lar protein-coding transcriptomes, regardless of whether they
were gonadal or extragonadal in origin (Palmer et al., 2008). As
seen for adult seminomas (Korkola et al., 2006), paediatric semi-
nomas were enriched for genes associated with pluripotency
and the undifferentiated state [e.g. NANOG, POU5F1 (OCT3/4),
TFAP2C and UTF] and paediatric YSTs were associated with
genes such as AFP, those involved in differentiation (KRT8,
KRT19), lipid metabolism (APOA1, APOA2) and proliferation
pathways (Palmer et al., 2008). Interestingly, global mRNA pro-
files also segregated paediatric cases from adult malignant
TGCTs of the same tumour subtype, suggesting that for mRNA
expression, histological subtype is the main discriminator, and
then patient age (Palmer et al., 2008) (Fig. 1). Alterations in hor-
monal status that accompany puberty may partly account for
the observed differences in mRNA expression profiles between
paediatric and adult GCTs. Subsequent to these studies, a prog-
nostic mRNA gene expression signature predictive of overall
survival was identified and validated in adult males with non-
seminomatous malignant GCTs (Korkola et al., 2009). Future
studies of GCTs affecting patients in both childhood and adoles-
cence will need to assess whether such an ‘adult’ mRNA signa-
ture is prognostic in these younger age-groups. If not, it will be
important to identify which specific biomarkers are predictive of
clinical outcome in paediatric and adolescent GCTs, to improve
risk stratification and management.
During the last decade, key insights into the molecular basis of
cancer have been elucidated, resulting in a growing understand-
ing of the complex cancer-associated signalling pathways that
underlie tumour formation and progression. Among these path-
ways, Wnt, TGF-beta/BMP, PI3K/AKT/mTOR, RAS/RAF and VEGF
signalling are of special interest, as they have driven the develop-
ment of a new generation of anti-cancer drugs which target spe-
cific molecular events/mutations (Murray & Sch€onberger, 2014).
Importantly, these pathways have also been identified as dysreg-
ulated in malignant GCTs, suggesting possible novel therapeutic
targets (Murray & Sch€onberger, 2014). The generally more
aggressive clinical behaviour of adult malignant GCTs in com-
parison with their paediatric counterparts is likely to be due, at
least in part, to the differential expression of individual protein-
coding genes within those pathways (Palmer et al., 2008). This
differential gene expression may be owing to a number of fac-
tors, including genomic copy number alterations (Palmer et al.,
Figure 1 Principal component analysis of paediatric and adult malignant
germ cell tumour (GCT) protein-coding gene expression data [adapted
from (Palmer et al., 2008)]. Each malignant GCT sample is represented by a
coloured circle; the number next to the circle shows the age of the relevant
patient in years. The distance between samples represents biological
(protein-coding transcriptome) differences. Consequently, those samples
clustering close together demonstrate biological similarity, whereas those
that are segregated are more dissimilar.
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2007) or differences in epigenetic mechanisms observed
between the two age-groups of patients.
Differential expression of genes involved in cancer-associated
signalling pathways has been shown between the two main pure
histological subtypes of childhood malignant GCTs, namely YSTs
and seminomas. An mRNA microarray analysis identified signifi-
cant differential expression of genes involved in the Wnt path-
way between these two subtypes (Fritsch et al., 2006). Besides
WNT13, beta-catenin was also differentially expressed and
showed nuclear translocation in over 50% of YSTs, in contrast to
seminomas, where this occurred rarely. These differences sug-
gested activation of Wnt signalling in YSTs. Subsequent gene
expression analysis of intra- and extracellular regulators of the
WNT pathway confirmed the differential expression of several
genes between the two subtypes, for example SFRP2 and DKK1,
predominantly owing to epigenetic mechanisms (Sch€onberger
et al., 2010). Methylation of the DNA of these genes is therefore
likely to account for the over-expression of Wnt/beta-catenin
pathway genes seen in YSTs (Fritsch et al., 2006; Palmer et al.,
2008). Similarly, differential protein-coding gene expression
leads to activation of the TGF-beta/BMP pathway in YSTs, in con-
trast to undifferentiated tumours such as seminomas, where
BMP pathway activity is absent (Fustino et al., 2011).
KIT and its ligand KITLG (steel factor) are not only involved in
normal PGC development, resulting in oogenesis and spermato-
genesis, but are also implicated in GCT development (Gilbert
et al., 2011). They are known to activate the PI3K/AKT/mTOR
and RAS/RAF pathway, and consequently, recent research has
focused on KIT/KITLG in GCTs. Several immunohistochemical
studies of adult GCTs detected KIT in seminomas in contrast to
non-seminomatous tumours such as YSTs (Bokemeyer et al.,
1996c; Kemmer et al., 2004; Nakai et al., 2005; Biermann et al.,
2007; Nikolaou et al., 2007). In addition, mutations in KIT in
codon 816 (exon 17) are associated with the development of
bilateral GCTs (Looijenga et al., 2003) and advanced stages of
ovarian dysgerminoma (Cheng et al., 2011). Genetic and protein
analysis identified different gain-of-function mutations in the
KIT gene (D816V, D816H) in seminomas, resulting in phosphor-
ylation of KIT and PI3K and therefore constitutive activation of
the PI3K pathway, even in the absence of KITLG (Nakai et al.,
2005). Unfortunately, although seminomas may harbour activat-
ing KIT mutations, responses in clinical studies of the KIT tyro-
sine kinase inhibitor imatinib mesylate have been disappointing,
with no complete or even partial remissions (Einhorn et al.,
2006). However, this is not entirely surprising as only those
patients with mutations in exon 11 of KIT tend to respond to
imatinib therapy. In vitro studies suggest that alternative tyro-
sine kinase inhibitors, such as dasatinib, which target exon 17
mutations, may be more promising as treatment options in vivo
(Schittenhelm et al., 2006).
In many human cancers, mutations in the KRAS or BRAF gene
lead to activation of the RAS/RAF pathway, resulting in over-
expression of its target MAPK1 (ERK). Although MAPK1 is glob-
ally expressed in adult GCTs, mutations of KRAS and BRAF are
rare events, pointing to the involvement of KIT as an upstream
protein in activation of RAS/RAF signalling (McIntyre et al.,
2005; Sommerer et al., 2005). Nevertheless, a European study
identified that the BRAF mutation V600E is detectable in a sub-
group of chemotherapy-resistant adult GCTs and correlates sig-
nificantly with the presence of microsatellite instability
(Honecker et al., 2009). Of note, however, this finding could not
be verified in a recent US study of adult patients with malignant
GCTs (Feldman et al., 2014), nor in a large cohort of paediatric
GCTs (Masque-Soler et al., 2012).
NON-PROTEIN-CODING GENE (MICRORNA)
EXPRESSION
The identification of molecular abnormalities that are shared
across the diverse spectrum of malignant GCTs is particularly
important, as these are likely to be of fundamental significance
in disease pathogenesis. MicroRNAs are short, non-protein-cod-
ing RNAs that regulate the expression of protein-coding genes
through interactions with binding sites in the 30 untranslated
region (30UTR) of target mRNAs, and whose expression profiles
are dysregulated in cancer (Palmer et al., 2010). MicroRNAs may
act directly as oncogenes or tumour suppressor genes through
their interactions with mRNA targets (Palmer et al., 2010). As
microRNA profiles reflect the developmental lineage of tumours
(Lu et al., 2005), it was speculated that undertaking microRNA
expression analysis in GCTs might identify such shared molecu-
lar abnormalities (Palmer et al., 2010).
Over-expressed tissue microRNAs
An early study revealed that the miR-371–373 microRNA clus-
ter was highly expressed in adult TGCTs (Voorhoeve et al., 2006),
suggesting that it may act as a potential novel oncogene in
TGCTs via inhibition of the tumour suppressor gene LATS2
(Voorhoeve et al., 2006). Subsequently, it was confirmed that the
miR-371–373 cluster was over-expressed in adult gonadal malig-
nant GCTs, when compared with normal testis controls (Gillis
et al., 2007).
Next, a global microRNA profiling study (n = 615 microRNAs)
reported data from 48 paediatric samples, including gonadal and
extragonadal (including intracranial) malignant GCTs (Palmer
et al., 2010), and compared the profiles obtained with those from
the adult gonadal GCT study described above (Gillis et al., 2007).
The majority of differentially expressed microRNAs in paediatric
GCTs were down-regulated (Palmer et al., 2010), consistent with
observations in other malignancies (Lu et al., 2005). However,
the most significant finding was that the miR-371–373 and miR-
302/367 clusters were over-expressed in all malignant GCTs,
independent of patient age (paediatric or adult), tumour histo-
logical subtype (YST, seminoma or EC) or anatomical site (gona-
dal or extragonadal) (Palmer et al., 2010). This finding was the
first common biological abnormality identified in all malignant
GCTs and was consistent with the presumed common origin of
GCTs from PGCs (Palmer et al., 2010). Importantly for potential
clinical use as highly sensitive and specific universal biomarkers
of malignant GCTs, the expression levels of the eight main micr-
oRNA members from the miR-371–373 and miR-302/367 clusters
accurately segregated malignant GCTs from the non-malignant
group, comprising fetal and gonadal control samples and benign
teratomas (Fig. 2) (Palmer et al., 2010).
As both the miR-371–373 and miR-302/367 microRNA clusters
are ESC-specific pluripotency markers (Suh et al., 2004; Thom-
son et al., 2006; Lakshmipathy et al., 2007; Barroso-del Jesus
et al., 2008; Laurent, 2008), the co-ordinate expression of
microRNAs from these clusters in malignant GCTs either repre-
sents the persistence of an embryonic pattern of microRNA
expression that is not present in normal, somatically
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differentiated tissues, or acquired re-expression, regulated by an
as yet undetermined mechanism(s) (Palmer et al., 2010). Of
potential functional significance, six of the eight main microR-
NAs from the miR-371–373 clusters were noted to contain an
identical ‘seed’ region at 50 nucleotide positions 2–7 (2–7nt), crit-
ical for determining binding specificity to mRNA targets (Palmer
et al., 2010). In addition to the universal miR-371–373 and miR-
302/367 over-expression findings, each subtype of malignant
GCT was additionally characterized by specific abnormalities of
microRNA expression (Palmer et al., 2010). Interestingly, how-
ever, the striking differences in mRNA expression that were pre-
viously observed between paediatric and adult malignant GCTs
(Palmer et al., 2008) were not reflected by similar differences in
microRNA expression profiles (Palmer et al., 2010).
As microRNAs regulate gene expression via translational
repression and mRNA destabilization (Gautier et al., 2004;
Esquela-Kerscher & Slack, 2006; Giraldez et al., 2006), the latter
resulting in mRNA expression changes (Lim et al., 2005; Calin &
Croce, 2006), matched global mRNA profiles were ranked by
expression change and then assessed by the Sylamer bioinfor-
matic algorithm (van Dongen et al., 2008). This analysis showed
that the identical seed region shared by microRNAs from the
over-expressed miR-371–373 and miR-302/367 clusters resulted
in a global down-regulation of target mRNAs in malignant GCTs
and was therefore of functional significance (Palmer et al.,
2010). Using Gene Ontology analysis, it was demonstrated that
these mRNA targets mediated important cancer-associated cel-
lular processes, such as signal transduction, cell cycle, develop-
ment and morphogenesis (Palmer et al., 2010). Interestingly, the
same microRNAs have been shown to be essential for regulating
G1-S transition and promoting rapid proliferation in ESCs (Wang
et al., 2008; Wang & Blelloch, 2009).
The profiles of the differentially expressed microRNAs that
segregated the two main pure histological subtypes of malig-
nant GCT, YST and seminoma, were very similar in both adult
and paediatric patients, and may account for the observed dif-
ferences in clinical outcome between the two tumour types
(Murray et al., 2010). In particular, further over-expression of
the miR-302/367 cluster was observed in YSTs compared with
seminomas, which resulted in the down-regulation of cancer-
associated protein-coding genes (Murray et al., 2010). Further-
more, in another study the relative miR-302/367 over-expres-
sion in YSTs was associated with increased bone morphogenetic
protein (BMP) signalling activity in YSTs (compared with semi-
nomas), presumably via multiple predicted mRNA targets in the
transforming growth factor–beta/BMP pathway (Fustino et al.,
2011).
Of note, the miR-371–373 cluster is involved in maintaining
the pluripotent state in ESCs and germline stem cells, whereas
miR-302/367 members are induced during the first stages of dif-
ferentiation (Zovoilis et al., 2008). As miR-302/367 expression is
lost in cells and tissues showing somatic differentiation (Suh
et al., 2004; Barroso-del Jesus et al., 2008), it is likely that levels
peak during early extraembryonic differentiation. If so, dynamic
changes in miR-302/367 levels in normal embryonic develop-
ment (Stadler et al., 2010) would be mirrored in GCTs showing
equivalent differentiation states (Murray et al., 2010). Those
GCTs with extraembryonic differentiation (i.e. YSTs and poten-
tially CHC) would display high levels compared with undifferen-
tiated tumours (seminomas), with a reduction to virtually
undetectable levels in somatically differentiated tumours (ter-
atomas) (Murray et al., 2010), in which microRNA profiles are
almost identical to normal gonadal tissues (Palmer et al., 2010).
Another study of childhood GCTs demonstrated DNA hyperme-
thylation in YSTs compared with seminomas, coincident with
higher levels of expression of the DNA methyltransferase,
DNMT3B (Jeyapalan et al., 2011). Of particular interest,
DNMT3B is a predicted target of the miR-29 family (miR-29a, -
29b and -29c). Consistent with these observations, the miR-29
family is under-expressed in YSTs, when compared with
miR−371−3p
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Figure 2 Differential expression of the miR-371–373 and miR-302/367 clusters in malignant germ cell tumours (GCTs) [adapted from (Palmer et al.,
2010)]. Hierarchical clustering analysis based on the eight main microRNAs from the miR-371–373 and miR-302/367 clusters (rows) segregates (A) paediat-
ric and (B) adult malignant GCT samples from non-malignant controls (comprising benign teratomas and normal gonadal controls) (columns). In the heat-
map, red represents relative microRNA over-expression and blue represents under-expression. Green columns = normal gonadal controls;
brown = teratoma; blue = seminoma; yellow = yolk sac tumour; red = embryonal carcinoma.
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seminomas (Palmer et al., 2010), and may account for clinical
differences in behaviour.
In summary, miR-371–373 and miR-302/267 cluster over-
expression occurs in all malignant GCTs, regardless of patient
age, histological subtype and anatomical site of disease (Palmer
et al., 2010). This is in contrast to mRNA profiles in malignant
GCTs, where no such universal findings were described (Palmer
et al., 2008). However, similar to mRNA profiles (Alagaratnam
et al., 2011), microRNA expression differences between each
individual histological subtype vs. control samples were identi-
fied, in addition to the key over-expressed miR-371–373 and
miR-302/367 clusters (Palmer et al., 2010). Another similarity to
protein-coding gene profiles are that there are microRNA expres-
sion differences between histological subtypes, for example
seminoma and YST (Murray et al., 2010). Discordant with the
findings for mRNA analysis (Fig. 1), there do not appear to be
any major microRNA expression differences within histological
subtypes by patient age (i.e. in paediatric vs. adult samples)
(Palmer et al., 2010).
Detection of serum microRNAs
Although the serum biomarkers alpha-fetoprotein (AFP) and
human choriogonadotrophin (HCG) assist malignant GCT diag-
nosis, they have limitations in sensitivity and specificity (Murray
& Nicholson, 2011). AFP is produced by YST components and
HCG predominantly by CHC; consequently neither marker is
raised in all cases of malignant GCT and both show elevations in
non-malignant conditions (Murray & Nicholson, 2011). A bio-
marker that offered greater sensitivity and specificity for diag-
nosing or monitoring malignant GCTs would therefore be of
considerable clinical value (Murray et al., 2011).
There are no reports demonstrating the clinical utility of
serum levels of protein-coding mRNAs in malignant GCTs.
Moreover, potential mRNA biomarkers can be subject to consid-
erable variation in levels, for technical as well as biological
reasons. In particular, mRNAs are inherently unstable at room
temperature and rapidly degrade in blood-based samples that
are not stored correctly (Rainen et al., 2002; Viprey et al., 2007).
Furthermore, a small study describing non-protein-coding XIST
transcripts in the plasma of male patients with TGCTs (Kawaka-
mi et al., 2004) had low sensitivity and has not been confirmed
by others.
In contrast, microRNAs released from tumour cells into the
bloodstream are stable because of protection from RNAse degra-
dation by packaging within membrane-bound exosome particles
(Caby et al., 2005; Valadi et al., 2007). MicroRNAs show stability
in serum samples subjected to multiple freeze–thaw cycles
(Chen et al., 2008; Mitchell et al., 2008) and in those left at room
temperature prior to processing (Mitchell et al., 2008). Further-
more, a good correlation exists between levels of individual
microRNAs in serum and plasma samples obtained from the
same patient (Mitchell et al., 2008). As a result, blood-based
microRNAs show considerable promise for cancer diagnosis and
monitoring (Murray et al., 2011).
The first report of serum microRNA expression in malignant
GCTs contained a detailed multiplexed qRT-PCR methodology
and demonstrated elevated serum levels of all eight main mem-
bers of the miR-371–373 and miR-302/367 clusters in the serum
of a paediatric patient compared with pooled normal serum
(Murray et al., 2011). Levels of miR-372 were over 700-fold
higher at malignant GCT diagnosis and fell to normal levels dur-
ing treatment and in uneventful clinical follow-up (Murray et al.,
2011). Further study of malignant GCTs, including TGCTs, across
a range of representative ages (paediatric and adult), anatomical
sites (gonadal and extragonadal) and histological subtypes (YST,
seminoma and EC) confirmed universal over-expression at diag-
nosis of serum levels of miR-372 and miR-367 (Fig. 3) (Murray &
Coleman, 2012). Importantly, the majority of the cases described
were marker-negative by serum AFP and HCG estimation. There
was a potential association between serum levels of both
Figure 3 MicroRNAs from the miR-371–373 and miR-302/367 clusters as novel serum biomarkers of malignant germ cell tumours (GCTs) [adapted from
(Murray & Coleman, 2012)]. Levels of miR-372 from the miR-371–373 cluster (left) and miR-367 from the miR-302/367 cluster (right) in the serum at the
time of diagnosis in eight malignant GCTs of different patient age, anatomical site and histological subtype. Key: EG, extragonadal; TGCT, testicular germ
cell tumour. Yellow columns = yolk sac tumour samples; red = embryonal carcinoma; blue = seminoma.
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miR-372 and miR-367 and total tumour volume at diagnosis
(Murray & Coleman, 2012).
Using the same qRT-PCR methodology (Murray et al., 2011;
Murray & Coleman, 2012), these initial findings have been
extended. Elevated levels of the three main microRNAs from the
miR-371–373 cluster were demonstrated in stage 1 TGCT
patients at the time of diagnosis compared with control serum,
and fell to normal levels within 5 days of orchidectomy (Belge
et al., 2012; Dieckmann et al., 2012). The majority of patients
described also had ‘marker-negative’ disease by serum AFP/
HCG quantification (Belge et al., 2012; Dieckmann et al., 2012).
In these studies, the highest serum levels were noted for miR-
371a-3p, which also fell the most dramatically following treat-
ment (Belge et al., 2012; Dieckmann et al., 2012). In addition, in
advanced stage cases, serum levels of miR-371–373 microRNAs
only reduced to the normal range after treatment with surgery
and chemotherapy (Dieckmann et al., 2012). Importantly, for
the benign teratoma cases included in the study, serum miR-
371–373 levels at the time of diagnosis were in the range of the
controls, demonstrating the potential clinical utility of these
serum microRNAs to distinguish malignant disease from tera-
toma, for which the management approaches may be very differ-
ent (Dieckmann et al., 2012).
Subsequently, a large collaborative serum microRNA qRT-PCR
study employed a pipeline using non-human spike-in RNAs to
control for technical variation in sample preparation (Gillis
et al., 2013). Across all the datasets studied, a consistent, highly
significant increase in the levels of four microRNAs (miR-371a-
3p, miR-372, miR-373 and miR-367) was observed in serum from
all patients with malignant GCTs at the time of diagnosis. Area
under the curve values in receiver operator characteristic analy-
ses were 0.88 (miR-371a-3p), 0.91 (miR-372), 0.96 (miR-373) and
0.94 (miR-367) (Gillis et al., 2013), significantly outperforming
AFP and HCG. Combined use of these four microRNAs with
AFP/HCG identified all diagnostic malignant GCT samples cor-
rectly. The sensitivity of each marker was between 80 and 90% at
a specificity cut-off of 90% (Gillis et al., 2013).
Thus, microRNAs of the miR-371–373 and miR-302/367 clus-
ters are emerging as promising bodyfluid biomarkers to improve
clinical management of malignant GCTs. A further potential
application has been identified by the recent demonstration of
elevated levels of these microRNAs in the cerebrospinal fluid of
patients with intracranial malignant GCTs (Terashima et al.,
2013). Possible applications therefore include diagnosis of
malignant GCTs in relatively inaccessible sites, such as the medi-
astinum, retroperitoneum or central nervous system, without
the need for surgery, disease monitoring during chemotherapy
and detection of subclinical tumour recurrence which may
reduce the need for serial surveillance CT imaging and its inher-
ent secondary cancer risks (Murray & Coleman, 2012). Together,
the accumulating data strongly indicate that prospective studies
of serum microRNAs in larger patient cohorts are warranted
(Murray & Coleman, 2012).
Under-expressed tissue microRNAs
Members of the lethal-7 (let-7) family of microRNAs, which
regulate cell proliferation (Johnson et al., 2007) and are impor-
tant tumour suppressor genes (Takamizawa et al., 2004), were
under-expressed in paediatric malignant GCTs when compared
with non-malignant control tissues (Palmer et al., 2010). These
microRNAs are specifically negatively regulated by the RNA
binding protein LIN28 (Viswanathan et al., 2008, 2009), which is
expressed at high levels in PGCs (West et al., 2009). Early studies
used immunohistochemistry (Cao et al., 2011a,b; Xue et al.,
2011) and RNA interference (Gillis et al., 2011) to investigate the
expression and some aspects of LIN28 function in malignant
GCTs. For example, LIN28 depletion in malignant GCT cells led
to down-regulation of stem cell markers such as OCT4/POU5F1
and NANOG, and induction of cell differentiation (Gillis et al.,
2011). However, LIN28 effects on let-7 expression were not
assessed in this work (Gillis et al., 2011). Subsequently, it was
shown that the low levels of let-7 observed in malignant GCTs
were directly attributable to abundant LIN28 expression (Murray
et al., 2013). As for miR-371–373 and miR-302/367 over-expres-
sion, let-7 under-expression in malignant GCTs was universal,
occurring regardless of patient age, histological subtype or site
of disease, thereby extending published reports describing pre-
dominantly or exclusively tumours from adult patients (Cao
et al., 2011a,b; Gillis et al., 2011; Xue et al., 2011). Interestingly,
all let-7 family members contained an identical 2–7nt seed
region and the reduced abundance of this seed in malignant
GCTs contributed to the subsequent up-regulation of important
cancer-associated protein-coding genes, including MYCN (Mur-
ray et al., 2013) (Fig. 4). Such post-transcriptional effects on
MYCN levels are likely to explain why MYCN is frequently over-
expressed in malignant GCTs (Alagaratnam et al., 2011) but
shows copy number gain at the MYCN 2p23.4 locus in only one
third of malignant GCTs from adult patients (Kraggerud et al.,
2002) and less than one fifth of paediatric cases (Palmer et al.,
2007).
Let-7 target 
de-repression
e.g. MYCN
High LIN28 
levels
miR-9, miR-30
miR-125, miR-181
down-regulation
Let-7
down-regulation
+
+
Increased 
cellular 
proliferation
Figure 4 Schematic of the dysregulated LIN28/let-7 axis in malignant germ
cell tumours (GCT)s. Let-7 down-regulation in malignant GCTs is attribut-
able to abundant LIN28 expression (Murray et al., 2013). In turn, this leads
to over-expression of let-7 targets (e.g. MYCN) and increased cellular prolif-
eration. Loss of direct negative feedback from let-7 maintains high LIN28
levels and let-7 repression. Other contributions to abundant LIN28 expres-
sion include other microRNAs that bind to the 30UTR of LIN28 transcripts,
but which are down-regulated in malignant GCTs (Palmer et al., 2010).
Taken together, these findings highlight the LIN28/let-7 axis as a novel ther-
apeutic target in malignant GCTs.
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In addition, low let-7 levels in malignant GCT cells resulted in
increased LIN28 expression, through a binding site in the LIN28
30UTR for the common let-7 seed region (Murray et al., 2013)
(Fig. 4). Other microRNAs, including miR-9 (Zhong et al., 2010),
the miR-30 family (Zhong et al., 2010), miR-125 (Wu & Belasco,
2005; Zhong et al., 2010) and miR-181 (Li et al., 2012) have all
been reported to down-regulate LIN28 in ESCs and cancer cells.
Importantly, these microRNAs have previously been identified
as being universally under-expressed in malignant GCTs (Mur-
ray et al., 2013). As copy number gain at the LIN28 locus
(1p36.11) is not a feature of malignant GCTs (Palmer et al.,
2007), down-regulation of these microRNAs is likely to be an
important further contributor to LIN28 over-expression (Murray
et al., 2013) (Fig. 4). Interactions disrupting this LIN28/let-7 axis
represent promising targets for novel therapies in malignant
GCTs. As well as depleting LIN28, an alternative strategy is direct
replacement of let-7 family members (Murray et al., 2013). Both
approaches would provide a molecular ‘switch’ effect that
should result in a sustained reversion of malignant GCT cell phe-
notype (Murray et al., 2013).
CONCLUSION
Our increasing knowledge of the biology of malignant GCTs
needs to be harnessed to improve outcomes for both adult
and paediatric patients. In particular, genomic and protein-
coding transcriptomic data confirm that malignant GCTs of
childhood are biologically distinct from those of adulthood
and provide evidence supporting the different management
approaches employed in patients of different ages. In contrast,
all malignant GCTs over-express the miR-371–373 and miR-
302/367 clusters regardless of patient age, histological subtype
or anatomical tumour site. The detection of elevated serum
levels of these microRNAs at the time of malignant GCT diag-
nosis, with levels falling after treatment, highlights the univer-
sal diagnostic potential of this finding. In addition, the
dysregulation of the LIN28/let-7 axis in all malignant GCTs
also suggests a pathway that may be a target for the develop-
ment of novel therapeutic agents.
Further studies are now required, integrating genomic
changes using high-resolution methods with combined analysis
of mRNA and microRNA expression profiles in malignant GCTs
from both adult and paediatric patients with good and adverse
clinical outcomes. These approaches are likely to identify regula-
tory pathways and networks associated with treatment sensitiv-
ity and resistance. In particular, such studies should aim to
define further the clinical relevance of age-specific biological
characteristics of malignant GCTs. These insights may assist the
optimal management of affected patients and identify biological
targets suitable for the development of novel therapeutic agents.
The ultimate aim of this approach will be to improve clinical
outcomes for this under-investigated patient group, both
through improved survival of patients with poor-risk disease and
reduced late-effects of treatment for those with low-risk disease.
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